| Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies L Fattore, E Marra, ME Pisanu, A Noto, C De Vitis, F Belleudi, ... Journal of translational medicine 11 (1), 180, 2013 | 54 | 2013 |
| MicroRNAs in melanoma development and resistance to target therapy L Fattore, S Costantini, D Malpicci, CF Ruggiero, PA Ascierto, CM Croce, ... Oncotarget 8 (13), 22262, 2017 | 48 | 2017 |
| miR-579-3p controls melanoma progression and resistance to target therapy L Fattore, R Mancini, M Acunzo, G Romano, A Laganą, ME Pisanu, ... Proceedings of the National Academy of Sciences 113 (34), E5005-E5013, 2016 | 48 | 2016 |
| Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer A Noto, C De Vitis, G Roscilli, L Fattore, D Malpicci, E Marra, L Luberto, ... Oncotarget 4 (8), 1253, 2013 | 32 | 2013 |
| Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells F Belleudi, E Marra, F Mazzetta, L Fattore, MR Giovagnoli, R Mancini, ... Cell Cycle 11 (7), 1455-1467, 2012 | 31 | 2012 |
| Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma L Fattore, D Malpicci, E Marra, F Belleudi, A Noto, C De Vitis, ME Pisanu, ... Oncotarget 6 (28), 24823, 2015 | 26 | 2015 |
| TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung A Ricci*, C De Vitis*, A Noto*, L Fattore, S Mariotta, E Cherubini, G Roscilli, ... Cell cycle 12 (11), 1696-1703, 2013 | 24 | 2013 |
| Selective targeting of point-mutated KRAS through artificial microRNAs M Acunzo, G Romano, G Nigita, D Veneziano, L Fattore, A Laganą, ... Proceedings of the National Academy of Sciences 114 (21), E4203-E4212, 2017 | 23 | 2017 |
| Toxicity of aflatoxin B1 towards the vitamin D receptor (VDR) P Costanzo, A Santini, L Fattore, E Novellino, A Ritieni Food and Chemical Toxicology 76, 77-79, 2015 | 21 | 2015 |
| Role of WT1–ZNF224 interaction in the expression of apoptosis-regulating genes G Montano, E Cesaro, L Fattore, K Vidovic, C Palladino, R Crescitelli, ... Human molecular genetics 22 (9), 1771-1782, 2013 | 19 | 2013 |
| Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma L Fattore, CF Ruggiero, ME Pisanu, D Liguoro, A Cerri, S Costantini, ... Cell Death & Differentiation 26 (7), 1267-1282, 2019 | 13 | 2019 |
| MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma L Fattore, A Sacconi, R Mancini, G Ciliberto Cytokine & growth factor reviews 36, 39-48, 2017 | 12 | 2017 |
| Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma ME Pisanu, M Maugeri-Saccą, L Fattore, S Bruschini, C De Vitis, E Tabbģ, ... Journal of Experimental & Clinical Cancer Research 37 (1), 1-17, 2018 | 11 | 2018 |
| Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists DA Fitzmaurice, G Accetta, S Haas, G Kayani, H Lucas Luciardi, ... British journal of haematology 174 (4), 610-623, 2016 | 11 | 2016 |
| Melanoma and immunotherapy bridge 2015 VGY Nanda, W Peng, P Hwu, MA Davies, G Ciliberto, L Fattore, ... Journal of Translational Medicine 14 (1), 65, 2016 | 8 | 2016 |
| miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma L Fattore, M Acunzo, G Romano, A Laganą, D Malpicci, ME Pisanu, ... Cancer Research 76 (14 Supplement), 1070-1070, 2016 | 3 | 2016 |
| ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors L Fattore, D Malpicci, E Marra, R Camerlingo, G Roscilli, F Belleudi, ... Journal of translational medicine 13 (S1), K3, 2015 | 3 | 2015 |
| CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions S Bruschini, S di Martino, ME Pisanu, L Fattore, C De Vitis, V Laquintana, ... Journal of cellular physiology 235 (3), 1877-1887, 2020 | 2 | 2020 |
| Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study L De Luca, PL Temporelli, C Riccio, L Gonzini, L Marinacci, ... European Heart Journal-Quality of Care and Clinical Outcomes 5 (4), 334-342, 2019 | 2 | 2019 |
| The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma L Fattore, R Mancini, PA Ascierto, G Ciliberto Expert opinion on therapeutic targets 23 (1), 53-68, 2019 | 2 | 2019 |
